Fundz
Funding, M&A and exec moves matched to your market, from $49/mo billed annually, or $79/mo quarterly. See plans and pricing.See plans →

Breakthrough biotech Immunobiota is raising $5 million in a Seed round for clinical trials of its oral therapy for type 1 diabetes.

PRIVATEAug 25, 2026•about 3 hours ago

Amount Raised

$5 Million

Round Type

Seed

MelbourneBiotechnologyHealth Care

Description

Immunobiota, a Melbourne startup, is developing IBT-100, the world’s first oral, non-immunosuppressive therapy for type 1 diabetes. The company intends to raise $5 million to accelerate clinical trials for its innovative treatment. Founded by Dr. Eliana Marino, the firm aims to address the underlying causes of T1D

Company Information

Company

Immunobiota

Location

Melbourne, Victoria, Australia

About

Immunobiota is a biotech company developing the world’s first oral, non-immunosuppressive therapy for type 1 diabetes. Founded in 2022, it is a Monash University spinout led by Dr. Eliana Marino. The company is focused on treating the underlying cause of type 1 diabetes rather than just managing symptoms. Their lead product, IBT-100, aims to retrain the immune system to stop attacking insulin-producing cells.

Don't miss Immunobiota's next move

Get an email the moment Immunobiota raises, hires an exec, or expands, usually minutes after it happens.

One email per event. Unsubscribe anytime.

Predictive Intelligence
Strategic

ML-powered predictions for Immunobiota's next move

Learn about Strategic plan

Immunobiota raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.